Patents by Inventor Sally Haas-Smith

Sally Haas-Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions related to joint inflammation diseases
    Patent number: 7807389
    Abstract: Disclosed are compositions and methods related to joint inflammation diseases. Disclosed is the relationship between osteoclasts and inflammatory joint diseases and osteoclast precursor cells.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: October 5, 2010
    Assignee: University of Rochester
    Inventors: Christopher T. Ritchlin, Sally A. Haas-Smith, Edward M. Schwarz
  • Methods and compositions related to joint inflammation diseases
    Publication number: 20060275834
    Abstract: Disclosed are compositions and methods related to joint inflammation diseases. Disclosed is the relationship between osteoclasts and inflammatory joint diseases and osteoclast cells.
    Type: Application
    Filed: March 15, 2004
    Publication date: December 7, 2006
    Inventors: Christopher Ritchlin, Sally Haas-Smith, Edward Schwarz
  • Methods and compositions related to joint inflammation diseases
    Publication number: 20040209316
    Abstract: Disclosed are compositions and methods related to joint inflammation diseases. Disclosed is the relationship between osteoclasts and inflammatory joint diseases and osteoclast precursor cells.
    Type: Application
    Filed: March 12, 2004
    Publication date: October 21, 2004
    Inventors: Christopher T. Ritchlin, Sally A. Haas-Smith, Edward M. Schwarz
  • Method of using tetracycline compounds to enhance interleukin-10 production
    Patent number: 6015804
    Abstract: The invention is a method of enhancing endogenous interleukin-10 production in mammalian cells and tissues, which includes administering an effective amount of a tetracycline derivative. The method also includes enhancing interleukin-10 production by administering an effective amount of the tetracycline derivative to a mammal. Preferred tetracycline compounds are tetracycline compounds which have been modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by excessive IL-1 and TNF .alpha. production.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: January 18, 2000
    Assignees: The Research Foundation of State University of New York, University of Rochester
    Inventors: Lorne M. Golub, Christopher T. Ritchlin, Robert A. Greenwald, Sally Haas-Smith, Susan A. Moak, Hsi-Ming Lee